10x Genomics, Inc.
TXG
NASDAQ·Healthcare·Biotechnology·Mkt cap $8.0B
$62.65
▼ -0.90%
P/E
-106.19
Mkt Cap
$8.0B
52-Wk Range
$11.16–$66.94
52-Week Range
$11.16 - $66.94
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 349.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary microfluidic chip technology enabling high-throughput single-cell analysis
- Comprehensive integrated platform with complementary solutions (single-cell and spatial)
- Strong recurring revenue model through consumables and reagent sales
- Extensive customer base and installed base creating switching costs
- Continuous innovation pipeline expanding application capabilities
Bear Case
1 risk
- High volatility (beta 2.1). Larger-than-normal price swings expected.
Growth
Stable outlook
Increasing adoption of single-cell analysis in drug discovery and development
Value
Deep value opportunity - significant discount to Healthcare IT & Services peers
Momentum
Hot
+114.7% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying TXG right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.14 vs -$0.24 consensus (+42.4% surprise). Revenue of $151.0M vs $146.7M expected (+3.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+42.4%
Revenue trend · last 8Q
—
-10%
+10%
+13%
-2%
+1%
-3%
-13%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$151.7M
$165.0M
$154.9M
$172.9M
$149.0M
$166.0M
$150.8M
$151.0M
Margins · last 8Q
Gross
74.5%
Operating
-12.9%
Profit
-11.9%
Wall Street consensus
11 analysts · 36% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
36%
Hold
64%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Sep 1, 2026
vs Industry
How TXG stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related